Thursday, December 10, 2015
Parkinson’s patients have some good news: Charles River Laboratories today announced a significant expansion of its work with small molecule LRRK2 inhibitors, funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). [Read More]
Amgen and Merck, known as MSD outside the U.S. and Canada, today announced a cancer immunotherapy collaboration to support a phase Ib/III study investigating BLINCYTO (blinatumomab) in combination with KEYTRUDA (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin’s lymphoma.
Nosopharm, a France-based biotechnology company specialized in the R&D of new antibacterial molecules, has been selected to join European Gram-negative Antibacterial Engine (ENABLE), a project working to advance the development of potential antibiotics against multidrug resistant Gram-negative infections.
Zymeworks, a Vancouver-based, privately held biotherapeutics company, has entered into a collaboration and license agreement with GlaxoSmithKline for the research, development and commercialization of novel Fc-engineered monoclonal and bi-specific antibody therapeutics that have been optimized for specific therapeutic effects.